Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2018-08-07 Director's Dealing
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'DGAP-DD: MorphoSys AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and person closely associated with them'. Section 1, 2, 3, and 4 detail the transaction, including the person's position ('Member of the managing body'), the nature of the transaction ('Disposal'), and specific price/volume data for share transactions. This content directly matches the definition for Director's Dealing.
2018-08-07 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction (purchase of shares) by an individual named Jens Holstein, who is a 'Member of the managing body' of MorphoSys AG. This content directly matches the definition for Director's Dealing reports.
2018-08-07 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This content directly matches the definition for Director's Dealing reports, which corresponds to the filing code DIRS. The document details a purchase of shares by Jens Holstein, a Member of the managing body.
2018-08-07 English
Half-yearly financial report 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-Year Report January – June 2018' and contains comprehensive financial statements (Consolidated Statement of Income, Balance Sheet, Cash Flows), notes, and a detailed management report for the six-month period. It is a substantive financial report rather than an announcement or summary, fitting the definition of an Interim/Quarterly Report. H2 2018
2018-08-02 German
MorphoSys AG Reports Second Quarter 2018 Financial Results (news with additional features)
Earnings Release Classification · 100% confidence The document explicitly states in the title and body that it reports the "Second Quarter 2018 Financial Results" and provides detailed financial tables comparing Q2 2018 results with Q2 2017, as well as results for the first six months of 2018. It also includes updated financial guidance for the full year 2018. This content structure—detailed financial performance review for a period shorter than a year (half-year/quarterly)—is characteristic of an Interim/Quarterly Report (IR). Although it is presented as a news release (DGAP-News), the core content is the comprehensive financial statement for the period, not just the highlights (which would be an ER). Since it is a comprehensive report for a period shorter than a year, the correct classification is IR. Q2 2018
2018-08-01 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a 'Total Voting Rights Announcement' released on 31.07.2018, referencing Article 41 of the WpHG (German Securities Trading Act). It explicitly details a 'Type of capital measure' which is a 'Conditional capital increase' and states the 'New total number of voting rights'. This type of announcement, which reports changes in the total number of shares/voting rights due to capital structure events (like conditional capital increases), fits best under the 'Share Issue/Capital Change' category (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a director's dealing report (DIRS).
2018-07-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.